Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options

Seminars in Oncology

Volumn 35, Issue 6, 2008, Pages 590-596

  Vora, Nilesh ^a   Reckamp, Karen L ^a,b  

^a Therapeutics Research   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GERIATRIC ASSESSMENT; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 56249083923     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.08.009     Document Type: Article

References (37)

1. Owonikoko T.K., Ragin C.C., Belani C.P., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25 (2007) 5570-5577
2. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94 (2002) 2766-2792
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
4. Fentiman I.S., Tirelli U., Monfardini S., et al. Cancer in the elderly: why so badly treated?. Lancet 335 (1990) 1020-1022
5. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
6. Jatoi A., Hillman S., Stella P., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials?. Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 9113-9119
7. Jennens R.R., Giles G.G., and Fox R.M. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 36 (2006) 216-220
8. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 (2004) 2720-2726
9. Alam N., Shepherd F.A., Winton T., et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 47 (2005) 385-394
10. Earle C.C., Tsai J.S., Gelber R.D., et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 19 (2001) 1064-1070
11. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
12. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. [abstract]. J Natl Cancer Inst 94 (2002) 173-181
13. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137
14. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 (1980) 25-32
15. Asmis T.R., Ding K., Seymour L., et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26 (2008) 54-59
16. Gridelli C., Langer C., Maione P., et al. Lung cancer in the elderly. J Clin Oncol 25 (2007) 1898-1907
17. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
18. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
19. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
20. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25 (2007) 1553-1561
21. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
22. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
23. Langer C., Hsu C., Curran W.J., Komaki R., Lee J.S., Byhardt R., et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. [abstract 1193]. Proc Am Soc Clin Oncol 21 (2002)
24. Schild S.E., Stella P.J., Geyer S.M., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 (2003) 3201-3206
25. Rocha Lima C.M., Herndon II J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94 (2002) 181-187
26. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
27. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
28. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91 (1999) 66-72
29. Kudoh S., Takeda K., Nakagawa K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 24 (2006) 3657-3663
30. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34 Suppl 4 (2001) S65-S69
31. Maione P., Perrone F., Gallo C., et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23 (2005) 6865-6872
32. Hainsworth J.D., Spigel D.R., Farley C., et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110 (2007) 2027-2034
33. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 26 (2008) 60-65
34. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
35. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 760-766
36. Oxnard G.R., Fidias P., Muzikansky A., et al. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol 2 (2007) 1029-1035
37. Kurishima K., Satoh H., Ishikawa H., et al. Lung cancer in the octogenarian. Gerontology 47 (2001) 158-160